GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » Cash And Cash Equivalents

MicroPort CardioFlow Medtech (HKSE:02160) Cash And Cash Equivalents : HK$1,165.0 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech Cash And Cash Equivalents?

MicroPort CardioFlow Medtech's quarterly cash and cash equivalents declined from Dec. 2022 (HK$2,084.15 Mil) to Jun. 2023 (HK$1,151.38 Mil) but then increased from Jun. 2023 (HK$1,151.38 Mil) to Dec. 2023 (HK$1,164.97 Mil).

MicroPort CardioFlow Medtech's annual cash and cash equivalents declined from Dec. 2021 (HK$2,707.98 Mil) to Dec. 2022 (HK$2,084.15 Mil) and declined from Dec. 2022 (HK$2,084.15 Mil) to Dec. 2023 (HK$1,164.97 Mil).


MicroPort CardioFlow Medtech Cash And Cash Equivalents Historical Data

The historical data trend for MicroPort CardioFlow Medtech's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech Cash And Cash Equivalents Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial 121.58 726.05 2,707.98 2,084.15 1,164.97

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,707.98 2,270.47 2,084.15 1,151.38 1,164.97

MicroPort CardioFlow Medtech Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


MicroPort CardioFlow Medtech  (HKSE:02160) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


MicroPort CardioFlow Medtech Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Microport Scientific Corporation 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech Headlines

No Headlines